(NASDAQ: CSTL) Castle Biosciences's forecast annual revenue growth rate of 0.73% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 9.2%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 19.67%.
Castle Biosciences's revenue in 2025 is $311,878,000.On average, 1 Wall Street analysts forecast CSTL's revenue for 2025 to be $8,798,493,609, with the lowest CSTL revenue forecast at $8,798,493,609, and the highest CSTL revenue forecast at $8,798,493,609.
In 2026, CSTL is forecast to generate $9,746,540,748 in revenue, with the lowest revenue forecast at $9,746,540,748 and the highest revenue forecast at $9,746,540,748.